Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
Catherine Z. Chen, Paul Shinn, Zina Itkin, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
Tia A. Tummino, Veronica V. Rezelj, Benoit Fischer, et al.
Science (2021) Vol. 373, Iss. 6554, pp. 541-547
Open Access | Times Cited: 192
Cellular host factors for SARS-CoV-2 infection
Jim Baggen, Els Vanstreels, Sander Jansen, et al.
Nature Microbiology (2021) Vol. 6, Iss. 10, pp. 1219-1232
Open Access | Times Cited: 187
DrugCentral 2021 supports drug discovery and repositioning
Sorin Avram, Cristian Bologa, Jayme Holmes, et al.
Nucleic Acids Research (2020) Vol. 49, Iss. D1, pp. D1160-D1169
Open Access | Times Cited: 181
A critical overview of computational approaches employed for COVID-19 drug discovery
Eugene Muratov, Rommie E. Amaro, Carolina Horta Andrade, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 16, pp. 9121-9151
Open Access | Times Cited: 181
Deep learning identifies synergistic drug combinations for treating COVID-19
Wengong Jin, Jonathan Stokes, Richard T. Eastman, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 39
Open Access | Times Cited: 144
Advanced Methods for Natural Products Discovery: Bioactivity Screening, Dereplication, Metabolomics Profiling, Genomic Sequencing, Databases and Informatic Tools, and Structure Elucidation
Susana P. Gaudêncio, Engin Bayram, Lada Lukić‐Bilela, et al.
Marine Drugs (2023) Vol. 21, Iss. 5, pp. 308-308
Open Access | Times Cited: 63
COVID-19 drug discovery and treatment options
Jasper Fuk‐Woo Chan, Shuofeng Yuan, Hin Chu, et al.
Nature Reviews Microbiology (2024) Vol. 22, Iss. 7, pp. 391-407
Closed Access | Times Cited: 21
Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles
Catherine Z. Chen, Miao Xu, Manisha Pradhan, et al.
ACS Pharmacology & Translational Science (2020) Vol. 3, Iss. 6, pp. 1165-1175
Open Access | Times Cited: 121
The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules
Kirill Gorshkov, Catherine Z. Chen, Robert Bostwick, et al.
ACS Infectious Diseases (2020) Vol. 7, Iss. 6, pp. 1389-1408
Open Access | Times Cited: 87
Comparison of viral RNA–host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2
Shaojun Zhang, Wenze Huang, Lili Ren, et al.
Cell Research (2021) Vol. 32, Iss. 1, pp. 9-23
Open Access | Times Cited: 83
Inhibitors of SARS-CoV-2 PLpro
Dale J. Calleja, Guillaume Lessène, David Komander
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 67
A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19
Ankita Khataniar, Upasana Pathak, Sanchaita Rajkhowa, et al.
COVID (2022) Vol. 2, Iss. 2, pp. 148-167
Open Access | Times Cited: 48
Cyanobacteria and Algae-Derived Bioactive Metabolites as Antiviral Agents: Evidence, Mode of Action, and Scope for Further Expansion; A Comprehensive Review in Light of the SARS-CoV-2 Outbreak
Biswajita Pradhan, Rabindra Nayak, Srimanta Patra, et al.
Antioxidants (2022) Vol. 11, Iss. 2, pp. 354-354
Open Access | Times Cited: 44
A guide to the use of bioassays in exploration of natural resources
Jerica Sabotič, Engin Bayram, ‪David Ezra‬‏, et al.
Biotechnology Advances (2024) Vol. 71, pp. 108307-108307
Open Access | Times Cited: 10
A High-Throughput Screening Pipeline to Identify Methyltransferase and Exonuclease Inhibitors of SARS-CoV-2 NSP14
Quinlin M. Hanson, Xin Hu, Sourav Pal, et al.
Biochemistry (2025)
Closed Access | Times Cited: 1
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
Philip L. Tzou, Kaiming Tao, Janin Nouhin, et al.
Viruses (2020) Vol. 12, Iss. 9, pp. 1006-1006
Open Access | Times Cited: 68
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
Jordi Rodon, Jordana Muñoz‐Basagoiti, Daniel Perez‐Zsolt, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 52
Recent advances in drug repurposing using machine learning
Fabio Urbina, Ana C. Puhl, Sean Ekins
Current Opinion in Chemical Biology (2021) Vol. 65, pp. 74-84
Open Access | Times Cited: 47
Biological activity-based modeling identifies antiviral leads against SARS-CoV-2
Ruili Huang, Miao Xu, Hu Zhu, et al.
Nature Biotechnology (2021) Vol. 39, Iss. 6, pp. 747-753
Open Access | Times Cited: 46
Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants
Jessica Hong, Hyung Joon Kwon, Raúl E. Cachau, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 18
Open Access | Times Cited: 33
Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort
Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, et al.
Scientific Data (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 30
Drug Repurposing Against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Sarah Aherfi, Bruno Pradines, Christian Devaux, et al.
Future Microbiology (2021) Vol. 16, Iss. 17, pp. 1341-1370
Open Access | Times Cited: 34
A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry
Miao Xu, Manisha Pradhan, Kirill Gorshkov, et al.
SLAS DISCOVERY (2022) Vol. 27, Iss. 2, pp. 86-94
Open Access | Times Cited: 23
Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents
Hoda Zarkoob, Anna Allué‐Guardia, Yu‐Chi Chen, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 23
The relevance of acid sphingomyelinase as a potential target for therapeutic intervention in hepatic disorders: current scenario and anticipated trends
Ishfaq Hassan Mir, Chinnasamy Thirunavukkarasu
Archives of Toxicology (2023) Vol. 97, Iss. 8, pp. 2069-2087
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top